ROME Therapeutics Secures $77 Million in Series B Financing to Advance Repeatome-derived Pipeline for Cancer and Autoimmune Diseases and Expand Repeatomics Platform

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/3nzBkRy
via IFTTT